title: Statistical refocusing in the design of Phase II trials offers promise of increased R&D productivity.
authors.affiliation: Biogen Idec, 14 Cambridge Center, Cambridge, Massachusetts 02142, USA.
authors.forename: Stacy R
authors.initials: SR
authors.lastname: Lindborg
authors.affiliation: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.
authors.forename: Charles C
authors.initials: CC
authors.lastname: Persinger
authors.affiliation: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.
authors.forename: Andreas
authors.initials: A
authors.lastname: Sashegyi
authors.affiliation: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.
authors.forename: Craig
authors.initials: C
authors.lastname: Mallinckrodt
authors.affiliation: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Ruberg
mesh_terms: D017322:Clinical Trials, Phase II as Topic / Q000379:methods*; D003627:Data Interpretation, Statistical; D017598:Efficiency, Organizational; D006801:Humans; D012107:Research Design; D013223:Statistics as Topic / Q000379:methods*
references.citation: Nat Rev Drug Discov. 2014 Jul;13(7):491-2
references.pmid: 24981356